Allogene Therapeutics (ALLO) Earnings Date, Estimates & Call Transcripts → The best trading strategy for markets right now (From DTI) (Ad) Free ALLO Stock Alerts $2.20 -0.10 (-4.35%) (As of 01:21 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 7EstimatedActual EPS (May. 13) -$0.38 Beat By $0.03 Consensus EPS (May. 13) -$0.41 Read Call TranscriptListen to Call Get Allogene Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALLO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALLO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALLO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Insiders Exposed$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. Allogene Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.58)($0.44)($0.51)Q2 20244($0.58)($0.35)($0.43)Q3 20244($0.59)($0.33)($0.43)Q4 20244($0.59)($0.34)($0.48)FY 202416($2.34)($1.46)($1.84)Q1 20253($0.49)($0.35)($0.41)Q2 20253($0.49)($0.36)($0.42)Q3 20253($0.50)($0.37)($0.43)Q4 20253($0.50)($0.39)($0.45)FY 202512($1.98)($1.47)($1.72)Q1 20261($0.46)($0.46)($0.46)ALLO Earnings Date and InformationAllogene Therapeutics last released its earnings data on May 13th, 2024. The reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Its quarterly revenue was down 26.7% on a year-over-year basis. Allogene Therapeutics has generated ($1.79) earnings per share over the last year (($1.79) diluted earnings per share). Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.50) to ($1.59) per share. Allogene Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off prior year's report dates.Read More Allogene Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/7/2024(Estimated)------- 5/13/2024Q1 2024($0.41)($0.38)+$0.03($0.38)$0.01 million$0.02 million 3/14/2024Q4 2023($0.47)($0.43)+$0.04($0.35)$0.05 million$0.02 million11/2/2023Q3 2023($0.53)($0.37)+$0.16($0.37)$0.05 million$0.04 million8/2/2023Q2 2023($0.59)($0.53)+$0.06($0.53)$0.01 million$0.04 million 5/3/2023Q1 2023($0.63)($0.68)($0.05)($0.68)$0.08 million$0.05 million 2/28/2023Q4 2022($0.71)($0.66)+$0.05($0.66)$0.06 million$0.05 million Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/2/2022Q3 2022($0.62)($0.58)+$0.04($0.58)$0.01 million$0.05 million 8/9/2022Q2 2022($0.61)($0.52)+$0.09($0.52)$0.08 million$0.09 million 5/4/2022Q1 2022($0.59)($0.56)+$0.03($0.56)$0.10 million$0.06 million 2/23/2022Q4 2021($0.61)($0.54)+$0.07($0.54)-$0.05 million 11/4/2021Q3 2021($0.56)($0.57)($0.01)($0.57)-$0.05 million 8/3/2021Q2 2021($0.55)($0.53)+$0.02($0.53)$0.95 million$0.04 million 5/4/2021Q1 2021($0.46)($0.25)+$0.21($0.25)$24.50 million$38.35 million 2/24/2021Q4 2020($0.56)($0.53)+$0.03($0.53)-- 11/9/2020Q3 2020($0.54)($0.52)+$0.02($0.52)-- 8/5/2020Q2 2020($0.54)($0.53)+$0.01($0.53)-- 5/6/2020Q1 2020($0.58)($0.58)-($0.50)-- 2/27/2020Q4 2019($0.68)($0.58)+$0.10($0.58)-- 11/5/2019Q3($0.54)($0.50)+$0.04($0.50)-- 8/7/2019Q2 2019($0.47)($0.4131)+$0.0569($0.41)-- Allogene Therapeutics Earnings - Frequently Asked Questions When is Allogene Therapeutics's earnings date? Allogene Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates. Learn more on ALLO's earnings history. Did Allogene Therapeutics beat their earnings estimates last quarter? In the previous quarter, Allogene Therapeutics (NASDAQ:ALLO) reported ($0.38) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.41) by $0.03. Learn more on analysts' earnings estimate vs. ALLO's actual earnings. How can I listen to Allogene Therapeutics's earnings conference call? The conference call for Allogene Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Allogene Therapeutics's conference call transcript? The conference call transcript for Allogene Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded annual revenue of $90,000.00. How much profit does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded net income of -$327.27 million. ALLO has generated -$1.79 earnings per share over the last four quarters. What is Allogene Therapeutics's EPS forecast for next year? Allogene Therapeutics's earnings are expected to decrease from ($1.50) per share to ($1.59) per share in the next year. More Earnings Resources from MarketBeat Related Companies: bluebird bio Earnings Results Neumora Therapeutics Earnings Results Sana Biotechnology Earnings Results Vir Biotechnology Earnings Results Cullinan Therapeutics Earnings Results BioCryst Pharmaceuticals Earnings Results Tarsus Pharmaceuticals Earnings Results 4D Molecular Therapeutics Earnings Results Autolus Therapeutics Earnings Results Ginkgo Bioworks Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple Stock All-Time Highs: Can AI Outweigh Earnings Jitters?CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry Shifts This page (NASDAQ:ALLO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.